CEO Kevin Sharer

The Amgen Tour of California's announcement last week that America's premier bicycle race will this year include a climb up the slopes of Mount Diablo provides the Bay Area an opportunity to show off one of its most underappreciated destinations. More: Editorials | Letters to the Editor  

Register with us today at http://www.shinesrooms.com/index.php?_controller=RegisterMember&_method=index to have free access to these research reports. The biotechnology industry started 2012 on a positive note as a whole but is facing a few headwinds.  

WASHINGTON (Reuters) - An advisory panel on Wednesday recommended that U.S. health regulators reject the use of Amgen Inc's drug Xgeva to delay the spread of prostate cancer to the bone, dimming the chance of a wider use for one of the company's key growth drivers.  

CHICAGO, Feb. 9, 2012 /PRNewswire/ -- Zacks Equity Research highlights Amgen, Inc. (Nasdaq: AMGN) as the Bull of the Day and Montpelier Re Holdings (NYSE: MRH) as the Bear of the Day. In addition, Zacks Equity Research provides analysis on Cisco Systems (Nasdaq: CSCO),Illumina...  

THOUSAND OAKS, Calif. (AP) — Amgen Inc. says its fourth-quarter profit fell 8.5 percent, as higher taxes and higher costs for drug production, sales and administration offset an increase in revenue. The world's largest biotech company says its net income was $934 million, or $1.08 per share, down from $1.02 billion, also $1.08 per share, a year earlier. Adjusted profit came to $1.04 billion, or $1.21 per share, down...